



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

October 14, 2015

AngioDynamics, Inc.  
Teri Juckett  
Regulatory Affairs Manager  
603 Queensbury Ave.  
Queensbury, New York 12804

Re: K151724

Trade/Device Name: AngioDynamics Mariner Angiographic Catheters  
Regulation Number: 21 CFR 870.1200  
Regulation Name: Diagnostic Intravascular Catheter  
Regulatory Class: Class II  
Product Code: DQO  
Dated: September 11, 2015  
Received: September 14, 2015

Dear Ms. Juckett:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman". The signature is written in a cursive style and is positioned above the typed name and title.

for  
Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K151724

Device Name

Angiodynamics Mariner Angiographic Catheters

Indications for Use (Describe)

Angiodynamics Angiographic Catheters are for use where angiographic diagnosis is indicated.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRASStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

**510(K) SUMMARY FOR THE  
ANGIODYNAMICS, INC. MARINER ANGIOGRAPHIC CATHETERS**

Date Prepared: 14 October 2015

**A. Sponsor:**

AngioDynamics, Inc.  
603 Queensbury Avenue  
Queensbury, NY 12804

**B. Contact:**

Teri L. Juckett  
Manager, Global Regulatory Affairs  
Tel: 518-795-1142  
Fax: 518-742-4323  
Email: [tjuckett@angiodynamics.com](mailto:tjuckett@angiodynamics.com)

**C. Device Name:**

|                       |  |
|-----------------------|--|
| Trade Name:           | AngioDynamics Mariner Angiographic Catheters                                   |
| Common/Usual Name:    | Angiographic Catheters   |
| Classification Name:  | Catheter, Intravascular, Diagnosis<br>(21CFR§870.1200, Class II, Pro-Code DQO) |
| Classification Panel: | Cardiovascular   |

**D. Predicate Device:**

|                         |  |
|-------------------------|--|
| Trade Name:             | AngioDynamics Mariner Angiographic Catheter                                    |
| Common/Usual Name:      | Angiographic Catheters   |
| Classification Name:    | Catheter, Intravascular, Diagnosis<br>(21CFR§878.4810, Class II, Pro-Code GEX) |
| Classification Panel:   | Cardiovascular   |
| Premarket Notification: | K112452  |

**E. Device Description:**

AngioDynamics Mariner Angiographic Catheters are sterile, single use, disposable devices designed to delivery radiopaque contrast media to selected sites in the vascular system. The AngioDynamics Mariner Angiographic Catheter is hydrophilicly coated at the distal end.

**F. Indications for Use:**

AngioDynamics Angiographic Catheter are for use where angiographic diagnosis is indicated.

**G. Intended Use:**

The intended use of the AngioDynamics Mariner Angiographic Catheters is to deliver radiopaque contrast media to the vasculature during angiographic procedures.

**H. Summary of Similarities and Differences in Technology Characteristics and Performance:**

The proposed device has similar materials, design, and technical characteristics as the predicate device. The purpose of this 510(k) submission is to introduce into commercial distribution a modified AngioDynamics Mariner Angiographic Catheter which includes a material change to the compound, used in the extrusion of the outer layer of the non-braided shaft.

**I. Performance Data:**

The proposed AngioDynamics Mariner Angiographic Catheter and the predicate AngioDynamics Mariner Angiographic Catheter are substantially equivalent to the specified predicate devices based on a comparison of technological characteristics and the results of non-clinical performance and material testing, which include:

- Static Pressure
- Tensile
- Friction
- Particulate
- Biocompatibility per ISO 10993-1

**J. Conclusion:**

The results of the non-clinical testing and a comparison of similarities and differences demonstrate that the proposed and predicate devices are substantially equivalent.